BioSpace News Archive

New location brings a comprehensive approach to Pre- and Post-Transplant testing to the island and supports the advancement of transplant patient care

Sotira, a Phoenix based biotech company is proud to announce the preliminary findings of preclinical safety and efficacy studies for its groundbreaking, patent-pending vaccine alternative that has shown in on-going preclinical testing to attenuate COVID-19 infection.

Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2020 of $1.01 per share on the company’s common stock.

The COVID-19 pandemic has had quite the impact on COPAN Diagnostics, Inc. On Tuesday, the 5 millionth UTM® was shipped off from the company’s new manufacturing facility in Carlsbad, CA, ready to play an integral part in the battle against this deadly virus.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the third quarter ended September 30, 2020

Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease will webcast an investor update at the virtual VIVA20 on Saturday, November 7 at 11:00 a.m. eastern time.

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the third quarter ended September 30, 2020 after the market closes on November 5, 2020.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2020 on Thursday, November 5, 2020, before the U.S. financial markets open.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that management will be presenting at the following upcoming virtual investor conferences. B. Riley Securities Liver Disease Therapeutic s Day Thursday, October 29, 2020 Panel discussion with Dr. Christian Marsolais, Senior Vice President and Chief Medi

The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock October 22, 2020.